Obesity and asthma prevalence have been increasing over the past decade. Epidemiological
evidence demonstrates that obesity results in an increased risk of developing incident …

Background Many patients with severe asthma rely on oral glucocorticoids to manage their
disease. We investigated whether benralizumab, a monoclonal antibody directed against the …

Objective Severe asthma is associated with substantial personal and economic burden;
maintaining disease control is the key management goal. Increased understanding of asthma …

Patients with COVID-19 are at high risk for thrombotic arterial and venous occlusions. Lung
histopathology often reveals fibrin-based blockages in the small blood vessels of patients …

Severe asthma often remains uncontrolled despite effective treatments and evidence-based
guidelines. A group of global experts in asthma and biologic medications from 9 countries …

Studies of patients with COVID-19 have demonstrated markedly dysregulated coagulation
and a high risk of morbid arterial and venous thrombotic events. Elevated levels of blood …

Background ANDHI was done to assess the efficacy of benralizumab, including onset of effect
and impact on health-related quality of life (HRQOL), exacerbation rate, lung function, and …

Severe cases of coronavirus disease 2019 (COVID-19) are regularly complicated by
respiratory failure. Although it has been suggested that elevated levels of blood neutrophils …

Introduction International registries provide opportunities to describe use of biologics for
treating severe asthma in current clinical practice. Our aims were to describe real-life global …

Rationale: Nitric oxide bioactivity, mediated through the formation of S-nitrosothiols (SNOs),
has a significant effect on bronchomotor tone. S-Nitrosoglutathione is an endogenous …